News

2008

July 26 - 31, International Conference on Alzheimer's Disease 2008. Adlyfe is please to be presenting two posters at ICAD 2008 and the satellite meetings. The schedule includes:

• Intranasal Administration Of Pronucleon Peptides For In Vivo Imaging Of Beta Amyloid In Alzheimer'S Disease -- Saturday, July 26, 2008, 2:00 pm - 2:30 pm and Sunday Jul 27, 2008 12:30 pm - 3:00 pm
• Specific Conformational Detection Of Beta-sheet Rich Amyloid Beta Proteins Using Conformationally Dynamic Pronucleon™ Peptides -- Tuesday Jul 29, 2008 12:30 PM - 3:00 PM

Please click here to download a brochure with Adlyfe's abstracts and presentation schedule.

May 20, Adlyfe invited to present at the 10th Anniversary C21 BioVentures, Private Life Science Conference, in Napa, California May 20 – 22, 2008. C21 BioVentures annually attracts a qualified and targeted audience of senior executives and decision makers from the biotechnology, pharmaceutical, and venture capital communities. The C21 conference is an opportunity to build relationships, network, and partner new innovative products and technologies. www.techvision.com/c21

March 27, Adlyfe to present on "Novel Fluorescence Based Diagnostic Assay For Detection Of Amyloid Beta Protein Biomarkers In Alzheimer’s Disease" at Keystone Symposia: Alzheimer's Disease in Keystone, CO. Dr. Renee Wegrzyn, Product Development Group Leader, will present on Thursday, March 27th during Poster Session 3, poster #321.

March 27, Dr. Alan Rudolph, CEO of Adlyfe, to present "Conformational Amyloid Proteins as Biomarkers for Neurodegenerative Disease" March 27th at CHI 15th International Molecular Medicine Tri-Conference in San Francisco, CA. www.tri-conference.com

2007

September 24, Adlyfe Appoints Gretchen L. Schieber as Vice President of Diagnostic Development. More...

September 17, Adlyfe Appoints Roxanne Duan as Vice President of Research. More...

August 29, Adlyfe Study on the Detection of Misfolded Proteins Published in the Journal Transfusion. More...

January 24, Adlyfe Strengthens IP Portfolio Surrounding Diagnostics for Alzheimer's and Other Diseases with Issuance of Landmark U.S. Patent. More...

2006

December 4, Adlyfe Inc. was one of thirteen companies chosen to present at Bio-Life-Tech Princeton 2006, an annual venture conference sponsored by Early Stage East. Adlyfe won the “Best Exhibiting Company” award.

October 6, Firm to test Alzheimer's detector. More...

September 26, Washington, DC—Adlyfe selected as one of fifteen companies to present before an audience of venture capitalists and industry professionals at 2006 Mid-Atlantic Bio: The Conference for Industry and Investors. The company investment presentations are a unique component of the premier annual gathering of the mid-Atlantic region's entire bioscience community, which also features a variety of sessions on business, policy and scientific topics. The conference will take place October 10-11 at the Ronald Reagan Building and International Trade Center in Washington, DC.

September 18, Adlyfe Presents at FDA TSE Advisory Meeting. Adlyfe Inc. was invited to present at the TSE Advisory Meeting held by the FDA on Sep 18, 2006. Dr. Kent Lohman, Vice President of Assay Development, presented an overview of Adlyfe's misfolded protein detection platform and the demonstrated use of PronucleonTM ligands for the early, presymptomatic detection of disease in both animals (Sheep scrapie, Bovine Spongiform Encephelopathy) and humans (Creutzfeldt-Jacob). Adlyfe Inc. is a biotechnology company located in Rockville, MD focused on early diagnosis and more effective treatment of neurodegenerative disorders correlated to misfolded amyloid proteins.

September 18, Adlyfe welcomes Dr. Michael Little as Chief Operating Officer. Dr. Little brings to Aldyfe nearly 20 years of experience and knowledge of the diagnostics and biotech industry. His background spans the continuum from basic technology development to product development to business. During his 16 years at BD, he was an inventor of BD's proprietary DNA amplification technology (SDA), was the Program Manager who brought to market the first FDA-cleared real-time DNA amplification instrument (BDProbeTecET), and was the WW leader for the molecular diagnostics business. His previous industrial experience includes product development roles at BioRad and Baxter Healthcare.

September 15, Adlyfe selected as a Main Stage Presenter at Southeastern Bio-Investor Forum in Atlanta, Georgia on Friday, November 10th at 12:25 PM.

July 18, "The Science of BSE 2: Blood" - DTN Online. More...

July 6, Adlyfe to present recent data on pronucleon ligands for detection of amyloid proteins at NeuroScience 2006 in Atlanta, Georgia. The poster presentation will be on Wednesday, October 18 from 1:00 PM - 2:00 PM. Poster session number 819.

March 1, Adlyfe welcomes Dr. Kent Lohman as Vice President of Assay Development. Dr. Lohman brings to Adlyfe 15 years of commercial experience in advanced diagnostic and assay development at companies including 454 Life Sciences, PE Applied Biosystems, and Becton Dickenson. Dr. Lohman has lead technology into profitable, market ready systems of reagents, instrumentation and software. Previous to joining commercial industry, Dr. Lohman spent 7 years in academic research programs in infectious disease at Yale University School of Medicine and Southwest Foundation for Biomedical Research. He managed critical programs within the Federal Government for both the Department of Defense and the Department of Energy. He has authored numerous peer-reviewed journal articles and is author on patents covering a variety of marketed technologies based on novel molecular and cellular mechanisms.

January 23, "Start-Up" - Washington Post Article. More...

January 17, Seth Rudnick and Ann Hanham to Join the Adlyfe Board of Directors. More...